Zacks Investment Research on MSN
Assurant (AIZ) earnings expected to grow: What to know ahead of next week's release
Assurant (AIZ) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a ...
The steps to solving it actually started with a golf physics lesson. And what I learned that day can help any golfer start on ...
Zacks Investment Research on MSN
Analysts estimate Corebridge Financial (CRBG) to report a decline in earnings: What to look out for
Wall Street expects a year-over-year decline in earnings on higher revenues when Corebridge Financial (CRBG) reports results ...
Super Bowl squares have become an American tradition nearly on par with the big game itself. But how do they work?
Sixty-one rods were unearthed between 2004 and 2008 in Xi'an, Shaanxi province, at the Qin Mausoleum of Shenheyuan for royalty during the Warring States Period (475-221 BC). Provided to China Daily ...
Like a true venture capitalist, state economic development secretary Eric Paley sees opportunity in the latest Census data.
Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability ...
Introduction Disability is linked to poor health outcomes and increased mortality, yet evidence on this relationship in sub-Saharan Africa is limited. This study investigated the association between ...
Welcome to the Immuneering conference call to discuss the positive 12-month overall survival update from the company's ongoing Phase IIa trial of atebemetinib in first-line pancreatic cancer patients.
At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and ...
Nonfarm payrolls growth totaled a seasonally adjusted 64,000 for the month, better than the Dow Jones estimate of 45,000 and up from a sharp decline of 105,000 in October. The unemployment rate rose ...
53% response rate in PD-L1 negative patients, comparing favorably to historical response of 23-32% with standard of care chemoimmunotherapy 60% response rate in 10 patients with STK11, KEAP1, and/or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results